STING1 and hepatocellular carcinoma: The overall depletion of B-cells significantly enhanced the efficacy of STING agonism, including when combined with STING agonist and anti-PD1 therapy, demonstrating the predominantly immunosuppressive role of B-cell populations during immunotherapy in HCC.